Upharmacia November 2017
PHARMA MARKET NEWS
Gedeon Richter See 22 % Sales
Increase in Ukraine in 9M2017
According to financial results published by Gedeon Richter , the company increased sales in Ukraine by 22.1 % y-o-y to USD 24.9 mio . The total sales grew by 19.1 % y-o-y to EUR 1.08 bn . Ukraine is among the company ’ s Top-10 external markets . Russia remains to be GR ’ s most profitable market . In 9M2017 , the sales in Russia grew by 25.3 % to EUR 237.6 bn . The US market sales showed 84.2 % increase vs 9M2016 .
In May 2017 , the Gedeon Richter in Ukraine changed its organization type from Public JSC to Private JSC . Moreover , the management board of the company was re-elected .
In 9M2017 , Gedeon Richter held 15th position on Ukrainian drug market by sales . The drug market saw 17.8 % y-o-y increase in the period .
Sanofi-Aventis Ukraine Preparing Claim Against Ukraine
Sanofi-Aventis Ukraine informed Ukrainian government that the company would appeal to the international investment arbitration against the state of Ukraine regarding the write-off of UAH 180 mio from the company ’ s accounts . In Jul 2017 , in accordance with the court decision , the UAH 46 mio were written off from the company ’ s accounts . In Oct 2017 , after the court dismissed the counterclaim of Sanofi-Aventis Ukraine , the State
Service imposed an arrest on the company ’ s bank accounts for the amount of almost UAH 140 mio .
Sanofi-Aventis Ukraine ’ s officials say that the company has become a victim of fraud , namely from the side of its former contractor LLC Hosse-Plex Ukraine , which had provided fabricated documents to the court . The pharmaceutical company filed a counterclaim against the decision of the courts of the lower instance and appellate instance to the higher business court of Ukraine referring to incomplete clarification of the circumstances of the case and incorrect application of the rules of substantive and procedural laws .
“ The current situation is treated very seriously ,” the Director of Sanofi-Aventis Ukraine Guilhem Granier said . “ Sanofi operates in more than 100 countries around the world , including developing countries , but none of them has faced similar events . Seeking to protect its rights and ensure unhindered work in the Ukrainian market Sanofi-Aventis Ukraine has sent a message to the Ukrainian government on international investment arbitration against the state of Ukraine .”
Mr . Granier noted that the fraudsters may continue to put pressure on the company , including - through state bodies . Currently , Sanofi-Aventis Ukraine has not stopped any of its projects and hopes for proper protection from the state authorities .
Ludmila Bezpalko to Head BCPP for 3 Years More
The Board of Borshchahivskiy Chemical-Pharmaceutical Plant ( BCPP ) extended powers of Ludmila Bezpalko at the position of the company ’ s CEO for three years more . Mrs . Bezpalko has been being the company ’ s head since 1993 .
In 9M2017 , BCPP held 20th position on Ukrainian retail drug marker by sales in values losing 3 positions vs 9M2016 . In 2016 , the company ’ s profit increased x2 y-o-y vs 2015 to UAH 118.7 mio . About 30 % of BCPP shares belong to Darnitsa company , which has been looking for ways to takeover the company .
Brazilian Regulatory Body Inspected Production Sites of Yuria-Pharm
The National Agency for Surveillance in the Healthcare of Brazil ( ANVISA ) inspected production sites of Ukrainian pharmaceutical company Yuria-Pharm . The body inspected the site for production of parenteral solutions of small volumes of filling that are amenable to thermal sterilization , sterile preparations of large volumes of filling , as well as non-sterile solutions . Receiving the Brazilian GMP certificate will allow Yuria-Pharm to import and sale its products on the Brazilian market . The results of the inspection will be issued within the month .
6 www . upharma-c . com